Efavirenz indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Efavirenz}} {{CMG}}; {{AE}} {{AZ}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect" |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Indications and Usage== | |||
SUSTIVA® (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32d6371e-ba56-4294-b732-6d43627c5c47 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 03:50, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
SUSTIVA® (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.[1]
References
Adapted from the FDA Package Insert.